BRPI0814479A2 - "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica" - Google Patents

"método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"

Info

Publication number: BRPI0814479A2
Authority: BR; Brazil
Prior art keywords: mmp; regulating; activity; specifically; metalloproteinase
Prior art date: 2007-08-15

Application number

BRPI0814479A

Other languages

English (en)

Inventor

Gabriel Rosenblum

Irit Sagi

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-15

Filing date

2008-08-07

Publication date

2016-07-12

2008-08-07 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2016-07-12 Publication of BRPI0814479A2 publication Critical patent/BRPI0814479A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Mycology (AREA)

BRPI0814479A 2007-08-15 2008-08-07 "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica" BRPI0814479A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US93548607P	2007-08-15	2007-08-15
PCT/IL2008/001082 WO2009022328A2 (en)	2007-08-15	2008-08-07	Regulators of mmp-9 and uses therof

Publications (1)

Publication Number	Publication Date
BRPI0814479A2 true BRPI0814479A2 (pt)	2016-07-12

Family

ID=40351257

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0814479A BRPI0814479A2 (pt)	2007-08-15	2008-08-07	"método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"

Country Status (14)

Country	Link
US (3)	US20110052572A1 (pt)
EP (2)	EP2185175B1 (pt)
JP (1)	JP2010536744A (pt)
KR (1)	KR20100071972A (pt)
CN (1)	CN102083455B (pt)
AU (1)	AU2008288082B2 (pt)
BR (1)	BRPI0814479A2 (pt)
CA (1)	CA2695969A1 (pt)
DK (1)	DK2185175T3 (pt)
ES (1)	ES2406105T3 (pt)
IL (1)	IL222302A (pt)
MX (1)	MX2010001657A (pt)
RU (1)	RU2474433C2 (pt)
WO (1)	WO2009022328A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0814479A2 (pt)	2007-08-15	2016-07-12	Yeda Res & Dev	"método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"
JP2011517662A (ja) *	2008-03-03	2011-06-16	ダイアックスコーポレーション	メタロプロテアーゼ９結合タンパク質
WO2012027721A2 (en)	2010-08-27	2012-03-01	Gilead Biologics, Inc	Antibodies to matrix metalloproteinase 9
JP5814800B2 (ja) *	2011-12-28	2015-11-17	株式会社Ｌｓｉメディエンス	神経変性疾患の検出方法
MD20140108A2 (ro)	2012-02-29	2015-03-31	Gilead Biologics, Inc.	Anticorpi împotriva metaloproteinazei 9 matriciale
EP2869837B1 (en)	2012-07-04	2016-09-14	F. Hoffmann-La Roche AG	Anti-theophylline antibodies and methods of use
MX354303B (es)	2012-07-04	2018-02-23	Hoffmann La Roche	Anticuerpos de anti-biotina y metodos de uso.
SG11201407420RA (en)	2012-07-04	2015-02-27	Hoffmann La Roche	Covalently linked antigen-antibody conjugates
EP3089758B1 (en)	2014-01-03	2021-01-27	F.Hoffmann-La Roche Ag	Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
BR112016014945A2 (pt)	2014-01-03	2018-01-23	F. Hoffmann-La Roche Ag	conjugado, formulação farmacêutica e uso
WO2015101586A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
CA3081058C (en) *	2015-01-16	2024-02-20	Academia Sinica	Linker units and their uses in configuring pharmaceutical molecules
US20200306283A1 (en)	2016-06-22	2020-10-01	William Warren HARLESS	Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
WO2020005891A1 (en) *	2018-06-25	2020-01-02	University Of Southern California	Compositions and methods for ameliorating tissue injury, enhancing liver regeneration and stem cell therapies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154600B (nl)	1971-02-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl)	1970-12-28	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en)	1971-06-21	1975-08-26	Biological Developments	Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en)	1971-09-01	1974-12-10	W Dreyer	Immunological reagent and radioimmuno assay
US3867517A (en)	1971-12-21	1975-02-18	Abbott Lab	Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl)	1972-05-11	1983-06-01	Akzo Nv	Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en)	1973-03-12	1974-11-26	H Mcconnell	Process for assaying for biologically active molecules
US3935074A (en)	1973-12-17	1976-01-27	Syva Company	Antibody steric hindrance immunoassay with two antibodies
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en)	1974-09-19	1977-07-05	The Board Of Trustees Of Leland Stanford Junior University	Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en)	1975-11-13	1976-10-05	General Electric Company	Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en)	1976-05-03	1977-07-19	The Massachusetts General Hospital	Composition and method for determining the size and location of myocardial infarcts
US4098876A (en)	1976-10-26	1978-07-04	Corning Glass Works	Reverse sandwich immunoassay
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en)	1980-09-19	1989-11-07	General Hospital Corporation	Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5011771A (en)	1984-04-12	1991-04-30	The General Hospital Corporation	Multiepitopic immunometric assay
US4666828A (en)	1984-08-15	1987-05-19	The General Hospital Corporation	Test for Huntington's disease
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4801531A (en)	1985-04-17	1989-01-31	Biotechnology Research Partners, Ltd.	Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5272057A (en)	1988-10-14	1993-12-21	Georgetown University	Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en)	1989-08-25	1993-03-09	Genetype Ag	Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es)	1990-08-29	2006-02-16	Genpharm International, Inc.	Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5189178A (en)	1990-11-21	1993-02-23	Galardy Richard E	Matrix metalloprotease inhibitors
US5239078A (en)	1990-11-21	1993-08-24	Glycomed Incorporated	Matrix metalloprotease inhibitors
US5281521A (en)	1992-07-20	1994-01-25	The Trustees Of The University Of Pennsylvania	Modified avidin-biotin technique
US6544761B2 (en) *	1994-12-13	2003-04-08	Human Genome Sciences, Inc.	Human tissue inhibitor of metalloproteinase-4
WO1997000449A1 (en) *	1995-06-14	1997-01-03	Aberdeen University	Prognostic and therapeutic system for cancer
US20020015997A1 (en) *	1997-06-16	2002-02-07	Lafferty William Michael	Capillary array-based sample screening
WO2000020860A1 (en) *	1998-10-08	2000-04-13	Calbiochem Novabiochem Corporation	Diagnostic assay for matrix metalloproteinase 9 and use thereof
AU2002235692A1 (en) *	2001-02-23	2002-09-04	Biophage Inc.	Methods and compositions for preventing and treating neutrophil-mediated diseases
SE0102298D0 (sv)	2001-06-27	2001-06-27	Astrazeneca Ab	Crystal structure of enzyme and uses thereof
WO2003006006A1 (en) *	2001-07-09	2003-01-23	The Regents Of The University Of California	Use of matrix metalloproteinase inhibitors to mitigate nerve damage
US7731648B2 (en) *	2001-07-25	2010-06-08	Aduro Biotech	Magnetic nanoscale particle compositions, and therapeutic methods related thereto
DE60325564D1 (de) *	2002-03-05	2009-02-12	Univ Texas	Biospezifische kontrastmittel
ATE517926T1 (de) *	2003-04-04	2011-08-15	Yeda Res & Dev	Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
FI20040572A0 (fi) *	2004-04-23	2004-04-23	Ctt Cancer Targeting Tech Oy	Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
WO2006037513A1 (en) *	2004-10-09	2006-04-13	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
BRPI0814479A2 (pt)	2007-08-15	2016-07-12	Yeda Res & Dev	"método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"

2008
- 2008-08-07 BR BRPI0814479A patent/BRPI0814479A2/pt not_active IP Right Cessation
- 2008-08-07 CN CN200880112385.3A patent/CN102083455B/zh not_active Expired - Fee Related
- 2008-08-07 KR KR1020107005028A patent/KR20100071972A/ko not_active Ceased
- 2008-08-07 RU RU2010108429/15A patent/RU2474433C2/ru not_active IP Right Cessation
- 2008-08-07 DK DK08789758.3T patent/DK2185175T3/da active
- 2008-08-07 JP JP2010520682A patent/JP2010536744A/ja active Pending
- 2008-08-07 EP EP08789758A patent/EP2185175B1/en not_active Not-in-force
- 2008-08-07 CA CA2695969A patent/CA2695969A1/en not_active Abandoned
- 2008-08-07 ES ES08789758T patent/ES2406105T3/es active Active
- 2008-08-07 MX MX2010001657A patent/MX2010001657A/es active IP Right Grant
- 2008-08-07 EP EP12198653.3A patent/EP2581445B1/en not_active Not-in-force
- 2008-08-07 WO PCT/IL2008/001082 patent/WO2009022328A2/en not_active Ceased
- 2008-08-07 US US12/673,524 patent/US20110052572A1/en not_active Abandoned
- 2008-08-07 AU AU2008288082A patent/AU2008288082B2/en not_active Ceased
2012
- 2012-10-09 IL IL222302A patent/IL222302A/en not_active IP Right Cessation
2013
- 2013-06-13 US US13/916,633 patent/US8999332B2/en not_active Expired - Fee Related
2015
- 2015-02-18 US US14/624,597 patent/US20150158953A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20110052572A1 (en)	2011-03-03
CN102083455A (zh)	2011-06-01
DK2185175T3 (da)	2013-05-13
IL222302A (en)	2016-07-31
EP2185175B1 (en)	2013-02-13
CN102083455B (zh)	2015-01-07
US8999332B2 (en)	2015-04-07
JP2010536744A (ja)	2010-12-02
EP2185175A4 (en)	2010-08-11
KR20100071972A (ko)	2010-06-29
AU2008288082A1 (en)	2009-02-19
EP2185175A2 (en)	2010-05-19
EP2581445B1 (en)	2015-04-08
WO2009022328A2 (en)	2009-02-19
US20130280247A1 (en)	2013-10-24
RU2474433C2 (ru)	2013-02-10
US20150158953A1 (en)	2015-06-11
RU2010108429A (ru)	2011-09-20
ES2406105T3 (es)	2013-06-05
WO2009022328A3 (en)	2010-03-04
CA2695969A1 (en)	2009-02-19
AU2008288082B2 (en)	2013-01-10
EP2581445A1 (en)	2013-04-17
MX2010001657A (es)	2010-03-15

Legal Events

Date	Code	Title	Description
2016-07-19	B15I	Others concerning applications: loss of priority
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0905752A2 (pt)	2015-12-01	"muteína de lipocalina da lágrima humana (htlc), molécula de ácido nucléico, célula hospedeira, composição farmacêutica, método para a produção de uma muteína de lipocalina da lágrima humana, método de tratamento de uma doença ou distúrbio e uso de uma mateína de lipocalina da lágrima humana"
BRPI0717219A2 (pt)	2015-05-26	"composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
BRPI0717697A2 (pt)	2016-03-22	composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0918194A2 (pt)	2015-12-01	''composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
BRPI0717822A2 (pt)	2013-11-12	Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto.
ECSP099833A (es)	2010-01-29	Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
CY2014042I1 (el)	2015-12-09	Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζολιου, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδος για την παραγωγη τους
BRPI1013763A2 (pt)	2015-08-25	Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
BRPI0916576A2 (pt)	2017-06-27	pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
BRPI0717902A2 (pt)	2013-10-29	"anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo"
BRPI0411743A (pt)	2006-08-08	método e composições para tratar doenças relacionadas a amilóides
BRPI0815708A2 (pt)	2014-09-30	Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição.
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0812770A2 (pt)	2014-12-02	Método in vitro para identificar uma pluralidade de moléculas antigênicas transportadas por eritrócitos de um indivíduo, e/ou identificar uma pluralidade de anticorpos contra moléculas antigênicas transportadas por eritrócitos, conjunto de reagentes para implementar o método de detecção .
BRPI0819916A2 (pt)	2015-05-19	Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.
BRPI0720169A2 (pt)	2013-12-24	Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0811262A2 (pt)	2014-11-04	Composto, composto ou sal do mesmo, composição farmacêutica, modulador de receptor de glicocorticóide, método para prevenção e/ou tratamento de bistúrbios metabólicos, doenças inflamatórias, doenças auto-imunes, doenças alérgicas, doenças do sistema nervoso central, doenças cardiovasculares, doenças relacionadas com homeostase ou glaucoma, e uso de pelo menos um composto ou um sal do mesmo
BRPI0815057A2 (pt)	2015-07-28	Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0718587A2 (pt)	2014-03-11	Uso de um composto, compostos, método de tratamento ou prevenção de doenças, processos para a preparação do composto e composição farmacêutica contendo o mesmo
BRPI0809680A2 (pt)	2014-10-07	Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de lxr alfa e/ou lxr beta e uso dos compostos.
BRPI0718586A2 (pt)	2014-03-11	Composto, processo para a sua preparação, composição farmacêutica contendo o mesmo, usos deste e método de tratamento ou prevenção de doenças